top of page

Ovarian drilling has traditionally been used as a treatment for infertility in non Clomid responsive patients with PCOS. It is a form of laparoscopic surgery that destroys ovarian tissue with the goal of restoring hormonal balance resulting in ovulation and pregnancy. LOD (Laparoscopic Ovarian Drilling) is considered underutilized mainly due to the need for general anaesthetic, particular Physician skills and appropriate facilities to perform the procedure. Ablacare aims to transform this technique into a procedure that can take place in a fertility clinic setting using a technique that is more minimally invasive and likened to the retrieval of eggs for IVF.

The AblaCare Device is being trialled for Transvaginal Ablation of Ovarian Tissue under ultrasound visualisation in women with PCOS infertility. The trial involves testing the safety and effectiveness of the AblaCare Kit. The kit contains two elements, the disposable device, and a radiofrequency energy generator. The Ablacare Device is a short-term invasive disposable device positioned through the vagina to deliver radiofrequency energy inside the ovary to ablate ovarian tissue. The trial is currently being carried out in two UK hospitals Royal Derby and Royal Hallamshire Hospital and we can't wait to read the outcomes.

© PCOS Vitality


62 views0 comments

Dr. Lourdes Ibañez, from the Hospital Sant Joan de Déu (Barcelona, Spain), coordinates the new European SPIOMET4HEALTH project: a new treatment for polycystic ovary syndrome in adolescents and young women

· The project, funded by the European Commission with €6 million, involves a consortium of 17 research groups from 9 European countries.

· SPIOMET4HEALTH will test a novel treatment to improve the quality of life of adolescents and young women suffering from Polycystic Ovary Syndrome (PCOS), a disorder affecting 5-10% of women worldwide.

SPIOMET4HEALTH is a new Horizon 2020 health project whose main objective is to study, in a multi-centric phase II clinical trial, a new treatment for PCOS in adolescent girls and young adult women.

The initiative, funded by the European Commission with a budget of 6 million euros, was launched on April 2021 and will last 5 years. SPIOMETH4HEALTH will test the efficacy of this new treatment for PCOS, the most common endocrine-metabolic disorder among women of reproductive age, affecting 5-10% of women worldwide.

This syndrome is the most frequent cause of anovulatory subfertility, and it is also associated with other lifelong disorders like type 2 diabetes, premenopausal cancer and anxiety/depression, with a negative impact on the health and quality of life of these subjects and their offspring.

Challenges and contribution of SPIOMET4HEALTH

Currently, there is no approved treatment for PCOS in adolescents and young women, and approximately 98% of them are prescribed oral contraceptives (OCs). OCs do alleviate key symptoms, however, they do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility.

Pilot studies developed by Dr. Lourdes Ibañez and other members of the consortium have identified a new treatment for PCOS based on the combination at low doses of three medications: spironolactone (SPI), pioglitazone (PIO) and metformin (MET): SPIOMET.

However, this treatment had some limitations: the medications used in these studies were combinations of generic products that had to be administered separately, resulting in the intake of three different tablets, raising potential compliance problems. In addition, these studies were conducted in small populations with limited ethnic variability and mostly in women without overweight or obesity, which limits the relevance of the results for this population ,who constitute approximately 50% of the PCOS patients.

SPIOMET4HEALTH aims to overcome these limitations by testing a novel treatment consisting of SPIOMET in a single tablet (SPI, 50 mg; PIO, 7.5 mg and MET, 850 mg) administered daily. Combining SPIOMET with lifestyle measures, the consortium aims at normalising ovulation and endocrine-metabolic status through reduction of hepato-visceral fat excess.

SPIOMET4Health may change the current paradigm of PCOS treatment by offering a pathophysiological approach, since the new therapy will focus not only on the gonadotropic axis but will also impinge on the underlying mechanisms responsible for the development of PCOS.

This approach is expected to reduce the number of persons affected, to improve the quality of life, and to lower the economic burden on European healthcare systems.

The design of SPIOMET4HEALTH foresees that the patients will be engaged over the entire timespan of the project and will also contribute to the ultimate study evaluation. The project incorporates an analysis of the patient’s quality of life that should provide the first large-scale evidence on the psychosocial benefits of the treatmetns studied. The analysis of the socioeconomic impact of the new therapy will allow to evaluate the direct and indirect costs for health systems and for society in the short, medium and long term.

(c) PCOS Vitality

DISCLAIMER: PCOS Vitality does not recommend any treatments or course of action. Not Medical Advice. If you require medical advice please speak to your Dr. PCOS Vitality is in no way connected with these studies.

61 views0 comments
  • Writer's picturePCOS Vitality (c)

It's almost September and in preparation for some of the forthcoming events we have planned we wanted to share our Facebook cover page which includes hashtags that you can follow to see what is happening or you can simply tag us in some of the activities you are doing yourself to raise awareness.

This is set to be an incredible month so get in touch and get involved! We'd love to hear from you.

(c) PCOS Vitality

15 views0 comments
bottom of page